Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Thoracic 1Other solid neoplasm 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1Mesothelioma, Malignant 1Melanoma 1Inflammatory Breast Neoplasms 1Glioblastoma 1COVID-19 1Adenocarcinoma of Lung 1

Interventions

Azacitidine 66venetoclax 21Decitabine 16Cytarabine 12decitabine and cedazuridine drug combination 10AP 1903 reagent 10Cyclophosphamide 7fludarabine 6pevonedistat 5mocetinostat 5ON 01910 5Busulfan 5treosulfan 4sabatolimab 4ruxolitinib 4cedazuridine 4cc-486 4Mycophenolic Acid 4Lenalidomide 4Injections 4plerixafor 3luspatercept 3imetelstat 3glasdegib 3fludarabine phosphate 3Whole-Body Irradiation 3Methotrexate 3GRN163L peptide 3Clofarabine 3CPX-351 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Myelodysplastic Syndromes × bemcentinib × Clear all
NCT06469138 2025-01-29

8479217

BerGenBio ASA

Phase 1 Completed
6 enrolled 17 charts
CNSDermatologicGastrointestinalMyeloidOther hematologic neoplasmOther solid neoplasmThoracic

Mesothelioma, Malignant, COVID-19, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Melanoma, Myelodysplastic Syndromes, Pancreatic Neoplasms, Leukemia, Myeloid, Acute

NCT02488408 2024-12-19

A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS

BerGenBio ASA

Phase 1/2 Completed
122 enrolled 29 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡